Darnytsa (Kyiv) pharmaceutical company in 2022 slightly reduced the production of drugs in physical terms – from 181 mln packs in 2021 to 173 mln packs in 2022, as the company informed Interfax-Ukraine news agency.
At the same time, according to its press release, Darnitsa occupies 15.7% of the Ukrainian pharmaceutical market, twice as much as its closest competitor.
“If in 2021 every seventh pack of drugs sold in pharmacies was made by “Darnitsa”, then in 2022 it is every sixth pack,” – according to the press release.
In total, in 2022 the company produced about 19 million packages of ampoules, 9 million packages of infusion solutions and 130 million packages of tablets and capsules.
At the same time, it is noted that “Darnitsa” has not stopped working since the first days of the full-scale war. In March it produced 60% of the pre-war volume of drugs, and in April it returned to pre-war production volumes in full.
PJSC “Pharmaceutical company “Darnitsa” is the leader of Ukrainian pharmaceutical market in physical terms. The company has been on the market for more than 90 years and manufactures 180 brands of drugs in 15 different forms. Strategic directions of portfolio development – cardiology, neurology, pain management.
The company was founded in 1930. According to the Uniform State Register of Legal Entities and Individual Entrepreneurs, the company’s ultimate beneficiary is Gleb Zagori.
